<DOC>
	<DOCNO>NCT02904252</DOCNO>
	<brief_summary>The primary objective ass prevalence genotype HCV infection thalassemia major thalassemia intermediate patient receive blood transfusion Department Medicine , Faculty Medicine Siriraj Hospital . The secondary objective identify effect HCV infection well risk factor advance liver disease liver cirrhosis patient The third objective identify role serum HA level fibrotest prediction cirrhosis patient .</brief_summary>
	<brief_title>The Prevalence Severity HCV Infection Thalassemia Major Thalassemia Intermedia Siriraj Hospital</brief_title>
	<detailed_description>Study protocol Data collection : The eligible patient ask participate study . After sign informed consent , patient ask complete questionnaire , clinical laboratory data patient retrieve out-patient electronic paper medical record , electronic laboratory result . The data include following : 1 . Clinical data - Demographic information ( age , gender , ethnicity , education , marital status ) - Family history liver disease - Current relevant medication - Weight , height body mass index ( BMI ) time enrollment - History blood blood product transfusion , last transfusion - History alcohol consumption - History active liver disease 2 . Laboratory data - Complete blood count - Iron study ( serum ferritin , serum iron , total iron binding capacity transferrin saturation ) - Hemoglobin type - HIV antibody status ( available ) - liver biochemistry include AST , ALT , albumin , globulin - Blood urea nitrogen , creatinine - HBsAg , Anti-HBsAb - Anti-HCV antibody - HCV RNA , HCV genotyping ( patient positive Anti-HCV ) - Serum hyaluronic acid - Fibrotest After data collection , patient receive blood test serum hyaluronic acid . If patient incomplete laboratory data ( except HIV antibody status ) , receive additional blood test miss data . All patient appoint transient elastography . All cost extra-investigation support study . Transient elastography ( TE Fibroscan ) : TE use evaluate liver fibrosis . TE perform patient examiner blind clinical , laboratory data . The right lobe liver target intercostal space access patient lie dorsal decubitus position right arm maximal abduction . With assistance TE , liver portion least 6-cm thickness , free large vessel , identify examination . The rate successful measurement interpret ratio number validate total number measurement . The result express median value total measurement kPa . Patients ascites excluded study due limitation result interpretation . Data Handling : Data patient collect OPD , Division Hematology Division Gastroenterology , Siriraj Hospital , Mahidol University , Bangkok , Thailand . The study start approve Ethics Committee ofSiriraj Hospital . Patients ' identification number store separate log book . Results report aggregate level , individual-level data never release . Sample Size Statistical analysis Sample size The primary research question study ass prevalence HCV infection thalassemia major thalassemia intermediate patient receive prior blood transfusion . From previous research conduct Wanachiwanawin W , et al , estimate prevalence hepatitis C viral infection thalassemia patient 20 percent . The sample size 246 sample accord calculation 95 % confident interval . Statistical analysis 1 . The quantitative data , age , analyze mean standard deviation mode median ( data n't normal distribution ) . The quantitative data , sex , analyze use percentage 95 % confident interval prevalence . 2 . In comparison two group , quantitative data , liver fibrosis : positive negative , compare use t-test ( normality ) Mann-Whitney U-test ( non-normality ) quantitative data analyze Chi-square test Fisher 's exact test . If result show statistically significance ( P-value &lt; 0.05 ) one value , Logistic Regression Analysis perform present odds ratio 95 % confidence interval .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>1 . Previously diagnose thalassemia major , example homozygous beta thalassemia beta thalassemia/hemoglobin E disease thalassemia intermedia hemoglobin H disease homozygous Hb CS 2 . Age equal 18 year 3 . Previous history blood transfusion 1 . Patients hepatocellular carcinoma , ascites pregnancy exclude study due limitation result interpretation . 2 . Unwilling participate 3 . Patient receive complete treatment hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Transient elastography</keyword>
	<keyword>Fibrotest</keyword>
</DOC>